GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VivoSim Labs Inc
The stock price of Organovo, a pioneer in 3D tissue bioprinting, reflects a long and complex history of attempts to commercialize this revolutionary technology. The chart is a story of high hopes, scientific challenges, and the search for a viable business model.
Share prices of companies in the market segment - Diagnostic medical equipment
Organovo is a pioneer in 3D bioprinting, developing technology to create functional human tissue for use in medical research. We've categorized it under "Diagnostic Equipment." The chart below shows the dynamics in the regenerative medicine sector.
Broad Market Index - GURU.Markets
Organovo is a pioneer in 3D bioprinting, developing technology to create functional human tissue for medical research. Its unique technology makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Organovo compares to it.
Change in the price of a company, segment, and market as a whole per day
VIVS - Daily change in the company's share price VivoSim Labs Inc
VivoSim Labs Inc.'s daily share price fluctuations reflect the high volatility inherent in 3D bioprinting companies. This metric measures the company's sensitivity to news about scientific breakthroughs and partnerships, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Diagnostic medical equipment
VivoSim Labs (Organovo) is involved in 3D tissue bioprinting, and its volatility reflects expectations for this futuristic technology. The chart below shows average daily price movements in the diagnostic equipment sector. This provides a benchmark for comparing how well VivoSim shares are performing relative to their industry peers.
Daily change in the price of a broad market stock, index - GURU.Markets
VivoSim Labs is a medical technology and diagnostics company. Its success depends on its ability to commercialize its unique developments. Shares of such small, innovative companies often exhibit high volatility, contributing to overall market "noise."
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VivoSim Labs Inc
The year-over-year performance of VivoSim Labs Inc., formerly known as Organovo, is a story of transformation. Its market cap change over the past 12 months reflects its strategic pivot to developing simulators for surgical training after struggling with 3D tissue bioprinting. Its valuation is a bet on success in a new, less ambitious, but more realistic niche.
Annual dynamics of market capitalization of the market segment - Diagnostic medical equipment
As a pioneer in 3D bioprinting, Organovo is a bet on the future of medicine. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its revolutionary, yet still experimental, technology for drug development.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organovo (ONVO), a pioneer in 3D bioprinting, has been a story about the future of medicine for years. Its volatile performance compared to the market reflects the long journey from scientific concept to commercial product. Investors are betting not on current revenues, but on the revolutionary potential of the technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VivoSim Labs Inc
VivoSim (formerly Organovo) is a biotechnology company focused on 3D tissue bioprinting. Its monthly performance reflects progress in its research programs and partnerships with pharmaceutical companies for drug testing.
Monthly dynamics of market capitalization of the market segment - Diagnostic medical equipment
VivoSim Labs, formerly Organovo, is a company that has historically pioneered the 3D bioprinting of human tissue. The dynamics of its sector, shown in the graph, reflect innovation in medicine. Against this backdrop, one can appreciate how its cutting-edge technologies, used for disease modeling and drug testing, are changing approaches to preclinical research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organovo (VIVS) is a pioneer in 3D bioprinting of human tissue. It's a venture capital story, and its shares are driven by news of technological advances. The chart will show high volatility, typical of companies whose valuation is based on future prospects and the ability to create a new industry, rather than current revenue.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VivoSim Labs Inc
VivoSim Labs, according to its website, develops technologies for 3D tissue bioprinting. The weekly stock price movements of such companies are a speculative bet on the future of regenerative medicine.
Weekly dynamics of market capitalization of the market segment - Diagnostic medical equipment
VivoSim Labs (Organovo) works in the field of 3D tissue bioprinting. This is at the cutting edge of science. The chart helps us understand: are the company's weekly stock price fluctuations a reaction to unique scientific breakthroughs or do they follow the general trend in the diagnostic and research equipment sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
VivoSim Labs, as a medical technology company, should be less dependent on economic cycles. The chart will show how insulated the company's shares are from general market fluctuations, moving with product news and regulatory decisions while ignoring macroeconomic noise.
Market capitalization of the company, segment and market as a whole
VIVS - Market capitalization of the company VivoSim Labs Inc
The data for VivoSim Labs (VIVS) may be inaccurate, as the website organovo.com is owned by a different company. The price chart of such a biotech stock would reflect investors' faith in 3D tissue bioprinting technology for drug testing and, potentially, future regenerative medicine.
VIVS - Share of the company's market capitalization VivoSim Labs Inc within the market segment - Diagnostic medical equipment
VivoSim Labs is likely related to Organovo, a pioneer in 3D tissue bioprinting. Its market capitalization in the diagnostic equipment segment reflects the potential of this futuristic technology. The company's weight reflects a bet that printed human tissue will become the standard for drug testing and, perhaps one day, for transplants.
Market capitalization of the market segment - Diagnostic medical equipment
VivoSim Labs, affiliated with Organovo, is working in the field of bioprinting. What is the scale of this futuristic idea? The chart below shows the overall market capitalization of the diagnostic equipment sector. Its dynamics reflect investors' assessment of the potential of tissue-generating technology for drug testing and future transplants.
Market capitalization of all companies included in a broad market index - GURU.Markets
The VivoSim Labs (formerly Organovo) chart is a visualization of the long and arduous history of this pioneer in 3D tissue bioprinting. Its market capitalization reflects all the challenges on the path from science fiction to commercially viable drug testing products. It's a chart full of hope and disappointment.
Book value capitalization of the company, segment and market as a whole
VIVS - Book value capitalization of the company VivoSim Labs Inc
For VivoSim Labs (Organovo), a pioneer in 3D tissue bioprinting, book value is its material foundation: laboratories, unique bioprinters, and technology rights. The chart shows how the value of this innovative scientific and technological base has changed.
VIVS - Share of the company's book capitalization VivoSim Labs Inc within the market segment - Diagnostic medical equipment
VivoSim Labs Inc. (likely private/defunct)—its strength lies in 3D bioprinting. Its assets are labs with unique bioprinters that create human tissue. The chart shows what share of this cutting-edge, future-oriented medical infrastructure the company controls.
Market segment balance sheet capitalization - Diagnostic medical equipment
VivoSim Labs is likely a biotech company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Their business requires investment in laboratories and, if successful, in manufacturing facilities to create their products.
Book value of all companies included in the broad market index - GURU.Markets
VivoSim Labs' (Organovo) assets are not organs, but laboratories and a unique 3D bioprinting technology for human tissue, which is used by pharmaceutical companies for drug testing. Its book value reflects its scientific potential in creating "living models" for research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VivoSim Labs Inc
VivoSim Labs (likely Organovo) was a pioneer in 3D tissue bioprinting. Its market capitalization (when active) reflected the enormous hopes for the technology. The chart was a story about the difficulty of turning futuristic science into a commercial product.
Market to book capitalization ratio in a market segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) was a pioneer in 3D tissue bioprinting. This chart reflects how the market perceived its revolutionary technology and its long and challenging path to medical commercialization.
Market to book capitalization ratio for the market as a whole
VivoSim Labs (Organovo) works in the field of 3D tissue bioprinting. Patents for this futuristic technology are its main asset. This chart shows how the market values companies that could revolutionize medicine and drug testing, assigning them high valuations long before they generate significant revenue.
Debts of the company, segment and market as a whole
VIVS - Company debts VivoSim Labs Inc
VivoSim Labs, affiliated with Organovo, is likely working in the field of 3D tissue bioprinting for medical research. This is a futuristic and highly capital-intensive technology. This chart shows how the company is raising significant funds to finance its expensive R&D, which could revolutionize drug testing and regenerative medicine.
Market segment debts - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) is a pioneer in 3D tissue bioprinting. Following setbacks, the company is in the process of restructuring and searching for a new strategy. This chart reflects its challenging financial position during this transition period.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VivoSim Labs Inc
VivoSim Labs (Organovo) has historically focused on 3D tissue bioprinting. This chart shows the financial structure of the company, which has undergone numerous transformations. Debt in this situation is an indicator of problems, as the company lacks a stable business to support it.
Market segment debt to market segment book capitalization - Diagnostic medical equipment
VivoSim Labs (Organovo) pioneered 3D bioprinting of human tissue for medical research. This futuristic technology requires massive investment. This chart shows the overall debt burden in the biotech sector, helping to understand the financial challenges companies at the forefront of science face in commercializing their discoveries.
Debt to book value of all companies in the market
VivoSim Labs (formerly Organovo) is working in the field of 3D bioprinting human tissue for use in medical research. This is a revolutionary technology. This chart shows that for such pioneering companies at the forefront of science, debt financing is impossible. Their future depends solely on shareholder support.
P/E of the company, segment and market as a whole
P/E - VivoSim Labs Inc
This chart shows the valuation of VivoSim Labs (Organovo), a company working in the field of 3D tissue bioprinting. P/E ratios are not applicable here. The company's valuation is a bet on the potential of its technology to find application in drug development and, in the long term, regenerative medicine.
P/E of the market segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) is a company developing bioprinting technologies to create functional human tissues for use in medical research and drug development. This chart shows the average valuation for the sector, helping to understand how the market views this futuristic regenerative medicine technology.
P/E of the market as a whole
Organovo (ticker symbol ONVO, not VIVS) is a pioneer in 3D bioprinting human tissue for use in drug development. Its valuation is a pure bet on this futuristic technology. It is not tied to the general economic cycles reflected here, but depends on the success of its developments and partnerships with pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VivoSim Labs Inc
VivoSim Labs (formerly Organovo) is a company focused on the development and commercialization of bioprinting technologies and human tissue engineering. This chart reflects investor expectations for the application of its technologies in preclinical research and drug development. The valuation is based on the potential of this cutting-edge scientific platform.
%20P%2FE%20VivoSim%20Labs%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VivoSim-Labs-Inc&v=1772636778271 "Chart of the company's future (projected) P/E VivoSim Labs Inc")
Future (projected) P/E of the market segment - Diagnostic medical equipment
VivoSim Labs, formerly Organovo, specializes in 3D bioprinting technologies for human tissue for medical research and drug development. Its valuation relative to other biotech companies reflects investors' views on the potential of its unique platform, betting that bioprinting will transform drug testing.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Diagnostic-medical-equipment&v=1772636778283 "Future (projected) P/E graph of the market segment - Diagnostic medical equipment")
Future (projected) P/E of the market as a whole
VivoSim Labs, formerly Organovo, was involved in 3D bioprinting of human tissue. The company has likely shifted focus but remains in the biotech space. This chart reflects investors' overall risk appetite, which is critical for biotech companies, especially those undergoing transformation or working on highly complex technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636778300 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VivoSim Labs Inc
VivoSim Labs, formerly Organovo, is a company focused on developing 3D human tissue for use in medical research and drug testing. The financial performance shown here reflects its transition from ambitious plans for 3D organ printing to a more pragmatic business model.
Profit of companies in the market segment - Diagnostic medical equipment
VivoSim Labs, affiliated with Organovo, works in the field of 3D tissue bioprinting for medical research. This chart shows the overall profitability of the diagnostic and research equipment sector. It helps understand how much the pharmaceutical industry is willing to pay for innovative technologies that can speed up drug testing.
Overall market profit
VivoSim Labs (formerly Organovo) focused on 3D bioprinting of human tissue for medical research. This is a deeply innovative field. The success of such companies depends on technological breakthroughs and scientific recognition, not the state of the economy, as reflected in this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VivoSim Labs Inc
VivoSim Labs, formerly Organovo, works in bioprinting and tissue engineering for medical research. The company's future profitability depends on the commercialization of its technologies. This chart shows analysts' expectations for demand for its services from pharmaceutical companies and research institutes.
%20profit%20of%20the%20company%20VivoSim%20Labs%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VivoSim-Labs-Inc&v=1772636778455 "Graph of future (projected) profit of the company VivoSim Labs Inc")
Future (predicted) profit of companies in the market segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) is a company likely focused on 3D tissue bioprinting technologies for medical research and drug development. This chart shows forecasts for the diagnostic equipment sector. It illustrates the potential of breakthrough technologies that could speed up and reduce the cost of developing new drugs by reducing the need for animal testing.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Diagnostic-medical-equipment&v=1772636778464 "Graph of future (predicted) profits of companies in a market segment - Diagnostic medical equipment")
Future (predicted) profit of the market as a whole
This chart illustrates investments in breakthrough medical technologies, such as 3D bioprinting. VivoSim Labs (formerly Organovo) depends on the availability of funding for such capital-intensive research. Economic growth and risk appetite are driving the industry's growth, but a downturn could slow it down.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636778486 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VivoSim Labs Inc
VivoSim Labs, formerly Organovo, was involved in 3D tissue bioprinting. This figure would reflect investors' belief in the revolutionary potential of this technology for drug testing and future organ transplants.
P/S market segment - Diagnostic medical equipment
VivoSim Labs, formerly Organovo, focused on developing 3D bioprinting technologies for creating functional human tissue. This chart shows the average valuation in the diagnostic medical equipment sector. It reflects investors' belief in the revolutionary potential of bioprinting for drug testing and regenerative medicine.
P/S of the market as a whole
VivoSim Labs Inc., formerly Organovo, has historically focused on 3D bioprinting of human tissue for research. The company is currently undergoing a transformation. Its valuation reflects both its legacy and its new prospects. This chart helps evaluate companies as they undergo a fundamental strategic shift and search for a new business model.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VivoSim Labs Inc
VivoSim Labs (formerly Organovo) was a pioneer in 3D bioprinting of human tissue but has shifted its focus. Future revenue depends on the success of its new strategy. The chart reflects the market's speculative assessment of the company's ability to find a new profitable niche after the failure of its core technology.
%20P%2FS%20VivoSim%20Labs%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VivoSim-Labs-Inc&v=1772636778508 "The graph of the company's future (projected) P/S VivoSim Labs Inc")
Future (projected) P/S of the market segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) was a pioneer in 3D bioprinting human tissue for medical research and drug development. The company faced challenges in commercializing its technology. This chart shows how the market assessed its chances of success compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Diagnostic-medical-equipment&v=1772636778514 "Future (projected) P/S market segment graph - Diagnostic medical equipment")
Future (projected) P/S of the market as a whole
This indicator reflects the market's faith in biotechnology. For VivoSim Labs, a company engaged in 3D bioprinting of human tissue, it is an indicator of the future of pharmaceuticals. Market optimism allows for funding the development of technologies that can replace animal testing of drugs and accelerate their market entry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636778551 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VivoSim Labs Inc
VivoSim Labs (formerly Organovo) was a pioneer in 3D bioprinting of human tissue for medical research and drug development. This chart reflects revenue from sales of printed tissue and research services. The company has shifted focus, and future revenue will depend on its new biotech ventures.
Sales of companies in the market segment - Diagnostic medical equipment
VivoSim Labs is likely connected to Organovo, a pioneer in 3D bioprinting of human tissue. This chart shows the dynamics in the diagnostic equipment sector. Bioprinting technology has enormous potential for drug testing and, in the future, for creating organs for transplantation, which could revolutionize medicine.
Overall market sales
VivoSim Labs Inc., formerly Organovo, focuses on the development and commercialization of diagnostic equipment. Its success depends on the introduction of innovations into medical practice. The overall economic environment, shown in this chart, influences labs' capital budgets and their willingness to invest in new, more advanced technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VivoSim Labs Inc
VivoSim Labs (formerly Organovo) is a company that has historically focused on 3D bioprinting of human tissue for medical research. It may now focus on developing diagnostic equipment. This chart reflects analysts' expectations regarding the company's new strategy and the commercialization of its technologies.
%20sales%20of%20the%20company%20VivoSim%20Labs%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VivoSim-Labs-Inc&v=1772636778604 "Schedule of future (projected) sales of the company VivoSim Labs Inc")
Future (projected) sales of companies in the market segment - Diagnostic medical equipment
VivoSim Labs, formerly Organovo, develops bioprinted tissues for medical research. This chart shows expectations for the medical diagnostics sector. It reflects the future of regenerative medicine, where 3D bioprinting could revolutionize drug testing.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Diagnostic-medical-equipment&v=1772636778609 "Schedule of future (projected) sales of companies in the market segment - Diagnostic medical equipment")
Future (projected) sales of the market as a whole
VivoSim Labs Inc., formerly known as Organovo Holdings, specializes in developing bioprinted human tissues for use in medical research and drug testing. The company's success depends on the acceptance of its technology by the pharmaceutical industry. This chart, reflecting pharmaceutical R&D budgets, demonstrates the industry's willingness to invest in advanced preclinical models.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636778636 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VivoSim Labs Inc
VivoSim Labs, formerly Organovo, works in the field of bioprinting and human tissue engineering. This chart shows the financial difficulties of this pioneer of this futuristic technology. Negative values reflect high R&D costs and difficulties in commercializing the technology for drug testing and regenerative medicine.
Market segment marginality - Diagnostic medical equipment
VivoSim Labs, formerly Organovo, develops and commercializes technologies for 3D bioprinting of human tissues used in medical research. Profitability in this cutting-edge field depends on demand from pharmaceutical companies. This chart, showing average profitability, serves as a benchmark for assessing the commercial potential of their technology.
Market marginality as a whole
VivoSim Labs (formerly Organovo) develops technologies for bioprinting human tissue. This overall market profitability chart doesn't impact its operations. Its success depends on scientific breakthroughs and the ability to create tissue for drug testing or future transplants. This is a long-term bet on revolutionizing medicine.
Employees in the company, segment and market as a whole
Number of employees in the company VivoSim Labs Inc
VivoSim Labs, formerly known as Organovo, was a pioneer in 3D tissue bioprinting. This timeline likely reflects a dramatic story: from a large scientific team at the height of its research to a dramatic downsizing following a strategic pivot and rebranding.
Share of the company's employees VivoSim Labs Inc within the market segment - Diagnostic medical equipment
VivoSim Labs Inc., operating in the diagnostic equipment sector, requires a strong team of engineers and scientists. This chart shows the percentage of biomedical engineers, software developers, and medical device manufacturing specialists the company attracts in its niche. It reflects its scientific and manufacturing capabilities, which are necessary for creating complex diagnostic systems.
Number of employees in the market segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) pioneered 3D bioprinting of human tissue for drug testing. This graph illustrates how advanced technologies could transform pharmaceutical R&D, potentially replacing animal testing and creating demand for bioengineers and cell biologists capable of "printing" living tissue.
Number of employees in the market as a whole
VivoSim Labs (formerly Organovo) worked in the field of 3D tissue bioprinting, a cutting-edge field in regenerative medicine. While the company faced challenges, its example illustrates the complex and risky nature of innovation. This graph reflects not only success stories but also the culmination of thousands of startups, each contributing to the overall progress.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VivoSim Labs Inc (VIVS)
VivoSim Labs (formerly Organovo) was a pioneer in 3D bioprinting of human tissue. This chart reflected the pure intellectual capital valuation. The company's value was based on its unique and futuristic technology. The chart showed how highly the market valued this breakthrough IP and its potential for medical applications and drug testing, based on a per-scientist basis.
%20of%20the%20company%20VivoSim%20Labs%20Inc%20(VIVS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VivoSim-Labs-Inc-VIVS&v=1772636778718 "Chart of market capitalization per employee (in thousands of dollars) of the company VivoSim Labs Inc (VIVS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
VivoSim Labs (Organovo) was a pioneer in 3D tissue bioprinting. The value of such companies lies in their revolutionary technology. The chart shows the investors' bets on their team of scientists and engineers. This is an assessment of the potential of their technology to transform pharmaceutical research and medicine.
%20by%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Diagnostic-medical-equipment&v=1772636778726 "Market capitalization per employee (in thousands of dollars) by market segment - Diagnostic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
VivoSim Labs Inc., formerly Organovo, developed 3D tissue bioprinting technology. This chart illustrates how the market assessed the potential of this revolutionary, yet difficult to commercialize, medical technology on a per-team basis.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636778737 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VivoSim Labs Inc (VIVS)
VivoSim (formerly Organovo) is a company focused on 3D tissue bioprinting. It's a deep R&D company. This chart shows the company's per-employee loss. It reflects how much the company is burning through per scientist trying to develop and commercialize this futuristic drug testing technology.
%20Chart%20VivoSim%20Labs%20Inc%20(VIVS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VivoSim-Labs-Inc-VIVS&v=1772636778764 "Company Profit Per Employee (in thousands of dollars) Chart VivoSim Labs Inc (VIVS)")
Profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
VivoSim Labs, formerly Organovo, focused on 3D bioprinting of human tissue for medical research. It's a disruptive but capital-intensive business. The negative profit per employee in this chart likely reflects the company's enormous R&D costs and the team of highly qualified scientists working on the technology, which will take time to commercialize.
%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Diagnostic-medical-equipment&v=1772636778780 "Chart of profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
VivoSim Labs (VIVS) (formerly Organovo) — (Little info, micro-cap) — a medtech company. Organovo was involved in 3D bioprinting (printing human tissue). It's an R&D hi-tech business. This chart shows the average profitability per employee across the market. For VIVS (which is not yet profitable), this is a benchmark: in biotech, IP allows for many times higher than this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636778797 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VivoSim Labs Inc (VIVS)
VivoSim Labs is a medical equipment company. This chart reflects the effectiveness of its business model, whether it's selling, leasing, or servicing diagnostic or therapeutic devices. It also demonstrates the demand for the company's products in medical institutions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VivoSim-Labs-Inc-VIVS&v=1772636778812 "Sales chart per company employee VivoSim Labs Inc (VIVS)")
Sales per employee in the market segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) is a company focused on the development and commercialization of 3D bioprinting technologies for human tissue research. This company has deep R&D capabilities. This chart shows the average revenue per employee in this segment. It serves as a benchmark, demonstrating the productivity of commercially successful biotech companies.
Sales per employee for the market as a whole
VivoSim Labs (VIVS) — *The ticker data for VIVS (formerly Organovo) is unclear.* Organovo was involved in 3D tissue bioprinting. This is an R&D platform. This metric is irrelevant, as the company is still in the development stage and has no commercial revenue from the sale of printed organs or tissues.
Short shares by company, segment and market as a whole
Shares shorted by company VivoSim Labs Inc (VIVS)
VivoSim Labs (VIVS) is apparently a shell company (formerly Organovo) that attempted to 3D print human tissue. The project failed. This chart shows bets that the company's assets are worthless. Bears expect shareholders to receive nothing after the liquidation, and the stock will depreciate to zero.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VivoSim-Labs-Inc-VIVS&v=1772636778884 "Short Shares Chart for the Company VivoSim Labs Inc (VIVS)")
Shares shorted by market segment - Diagnostic medical equipment
VivoSim Labs Inc (VIVS), formerly Organovo, has historically focused on 3D bioprinting of human tissue for research but is now shifting its focus. This chart shows the cumulative short position in the medical diagnostics sector. Its growth signals investor doubts about the commercial viability of 3D bioprinting technologies for R&D.
Shares shorted by the overall market
VivoSim (VIVS) is an R&D company developing medical devices. It's a speculative bet. When this market fear indicator rises, investors' risk appetite plummets. They sell off unprofitable stocks, like VIVS, whose fate depends on R&D and regulatory approval.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VivoSim Labs Inc (VIVS)
VivoSim Labs (VIVS), formerly Organovo, has expertise in 3D bioprinting human tissue for drug testing. This technology could transform pharmaceutical R&D. This oscillator measures price momentum. It helps identify when stocks are "overheated" (above 70) on breakout news or "oversold" (below 30) due to a long research cycle.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VivoSim-Labs-Inc-VIVS&v=1772636778948 "RSI 14 indicator chart for the company's stock VivoSim Labs Inc (VIVS)")
RSI 14 Market Segment - Diagnostic medical equipment
VivoSim Labs (formerly Organovo) is a pioneer in 3D bioprinting. The company creates functional human tissues in vitro (such as liver tissue), which are used by pharmaceutical companies for drug testing. This graph tracks the collective sentiment in the regenerative medicine sector. It helps us understand whether the VIVS momentum is part of the general hype or its unique technology.
RSI 14 for the overall market
VivoSim Labs (VIVS), a medical equipment developer, sees both hospital budgets and risk appetite in this chart. In a euphoric mood, investors are ready to finance the "future of medicine," while hospitals are eager to buy expensive innovations. In a panic, investors flee unprofitable R&D projects, and hospitals are freezing capital expenditures.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VIVS (VivoSim Labs Inc)
Organovo (VIVS) is a pioneer in 3D bioprinting of human tissue for use in R&D (drug testing) and, potentially, therapeutics. This chart shows the average analyst forecast. Their targets are based on progress in R&D, partnerships with pharmaceutical companies, and the long-term potential of regenerative medicine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VIVS-VivoSim-Labs-Inc&v=1772636779014 "A chart showing analyst consensus forecasts for the expected stock price. VIVS (VivoSim Labs Inc)")
The difference between the consensus estimate and the actual stock price VIVS (VivoSim Labs Inc)
VivoSim Labs (Organovo) is a pioneer in 3D bioprinting. The company uses its technology to "print" human tissue for R&D and drug testing. This chart measures the gap between the current price and the consensus target price, indicating whether experts believe this futuristic technology can be commercialized.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VIVS-VivoSim-Labs-Inc&v=1772636779015 "A chart showing the difference between the consensus forecast and the actual stock price. VIVS (VivoSim Labs Inc)")
Analyst consensus forecast for stock prices by market segment - Diagnostic medical equipment
VivoSim Labs (Organovo) is a pioneer in bioprinting. The company develops 3D printing technology for human tissue (such as liver) for drug testing. This chart shows analysts' overall expectations for the diagnostics sector. It reveals whether experts believe in the R&D-on-a-chip revolution or consider the sector speculative.
Analysts' consensus forecast for the overall market share price
VivoSim Labs (VIVS) is likely connected to Organovo, a pioneer in bioprinting. They were attempting to 3D print human tissue for R&D and, potentially, transplantation. This is futuristic science. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but extremely expensive, R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VivoSim Labs Inc
VivoSim Labs (Organovo) is a pioneer that fell. They were leaders in 3D bioprinting (printing living human tissue, such as the liver, for R&D). This chart is a summary of their battle for survival. It reflects their (almost complete) destruction of their business and their desperate attempts to reboot and find a new, viable business model.
AKIMA Market Segment Index - Diagnostic medical equipment
VivoSim Labs (VIVS), known as Organovo, is at the forefront of medicine. The company is a pioneer in 3D bioprinting, creating functional human tissues (such as livers) for R&D and drug testing. This chart shows the average index for the segment, helping to assess how this futuristic organ printing technology compares to the industry average.
The AKIM Index for the overall market
VivoSim Labs (Organovo) is a pioneer in 3D bioprinting of human tissue for research and therapeutics. This chart, reflecting the market average, is a backdrop. It helps assess how VIVS, a scientific platform, compares to overall macroeconomic trends.
